Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Click here to sign up for SAGE Journal Email Alerts today!

Sign In to gain access to subscriptions and/or personal tools.
Nutrition in Clinical Practice
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Onaca, N.
Right arrow Articles by Levy, M. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Onaca, N.
Right arrow Articles by Levy, M. F.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Invited Reviews

Pancreatic Islet Cell Transplantation: A Treatment Strategy for Type I Diabetes Mellitus

Nicholas Onaca, MD
Goran B. Klintmalm, MD, PhD
Marlon F. Levy, MD

Transplant Services, Baylor University Medical Center, Dallas, Texas

Correspondence: Correspondence: Nicholas Onaca, MD, Transplant Services, Baylor University Medical Center, 3500 Gaston Avenue, Dallas, TX 75246. Electronic mail may be sent to nicholao{at}baylorhealth.edu.

Type I diabetes mellitus continues to be a serious disease with long-term morbidity from complications of the disease, despite better knowledge of physiology and better patient care. Pancreatic islet cell transplantation, still experimental, is gaining acceptance as a treatment strategy for individuals with type 1 diabetes who have poor glucose control and frequent hypoglycemic episodes despite maximal care. The procedure can improve glucose control, avoiding further hypoglycemic episodes, and can achieve insulin-independence at the expense of immunosuppression treatment. Islet cell transplantation does not correct all the metabolic abnormalities seen in type 1 diabetes, and glucose tolerance can remain abnormal. The dietary management of the patients still needs to be defined. Further research is focused at improvement in islet isolation and the refinement of immunosuppression strategies aiming toward immune tolerance, bringing hope for a cure of diabetes.

Nutrition in Clinical Practice, Vol. 19, No. 2, 154-164 (2004)
DOI: 10.1177/0115426504019002154
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 Nutr Clin PractHome page
N. Onaca, B. Naziruddin, S. Matsumoto, H. Noguchi, G. B. Klintmalm, and M. F. Levy
Pancreatic Islet Cell Transplantation: Update and New Developments
Nutr Clin Pract, October 1, 2007; 22(5): 485 - 493.
[Abstract] [Full Text] [PDF]

Home page
 DiabetesHome page
T. B. Gibson, M. C. Lawrence, C. J. Gibson, C. A. Vanderbilt, K. McGlynn, D. Arnette, W. Chen, J. Collins, B. Naziruddin, M. F. Levy, et al.
Inhibition of Glucose-Stimulated Activation of Extracellular Signal-Regulated Protein Kinases 1 and 2 by Epinephrine in Pancreatic {beta}-Cells.
Diabetes, April 1, 2006; 55(4): 1066 - 1073.
[Abstract] [Full Text] [PDF]